SINOPHARM (01099) · Company profile · Eqvero

SINOPHARM

01099HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	575.17 bn CNY	584.51 bn CNY	596.57 bn CNY	552.15 bn CNY	521.05 bn CNY
Cost of revenue	529.21 bn CNY	535.52 bn CNY	543.63 bn CNY	500.55 bn CNY	473.08 bn CNY
Selling, general and administrative expense	24.03 bn CNY	25.58 bn CNY	26.16 bn CNY	24.91 bn CNY	23.21 bn CNY
Operating profit after depreciation	17.23 bn CNY	17.82 bn CNY	22.32 bn CNY	22.76 bn CNY	20.98 bn CNY
Operating profit before depreciation	21.52 bn CNY	22.55 bn CNY	26.75 bn CNY	26.93 bn CNY	24.91 bn CNY
EBIT	17.23 bn CNY	17.82 bn CNY	22.32 bn CNY	22.76 bn CNY	20.98 bn CNY
EBITDA	21.52 bn CNY	22.55 bn CNY	26.75 bn CNY	26.93 bn CNY	24.91 bn CNY
Interest expense	2.31 bn CNY	2.73 bn CNY	2.97 bn CNY	3.53 bn CNY	3.76 bn CNY
Profit before tax	14.8 bn CNY	14 bn CNY	19.51 bn CNY	18.56 bn CNY	17 bn CNY
Income tax expense	3.97 bn CNY	3.58 bn CNY	4.5 bn CNY	4.22 bn CNY	3.94 bn CNY
Income before extraordinary items	7.16 bn CNY	7.05 bn CNY	9.05 bn CNY	8.53 bn CNY	7.76 bn CNY
Common dividends	2.15 bn CNY	2.12 bn CNY	2.71 bn CNY	2.56 bn CNY	2.34 bn CNY
Total dividends	2.15 bn CNY	2.12 bn CNY	2.71 bn CNY	2.56 bn CNY	2.34 bn CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.